Avantor Completes Acquisition of Masterflex
Following the acquisition, Avantor will have access to Masterflex’s various bioproduction operations.
Avantor announced on Nov. 1, 2021, that it had completed a previously announced acquisition of the Masterflex bioprocessing business and its related assets from Antylia Scientific, a portfolio company. Masterflex is an Illinois-based manufacturer of peristaltic pumps and aseptic single-use fluid transfer technologies.
According to a company press release, the Masterflex acquisition is intended to strengthen Avantor's offering in bioproduction platforms such as monoclonal antibodies, cell and gene therapy, and messenger-ribonucleic acid. Masterflex also supports both therapy and vaccine manufacturing, including those related to COVID-19.
"The acquisition of Masterflex extends Avantor's single-use offering and gives us a complete end-to-end solution for aseptic fluid transfer throughout the bioproduction workflow," said Michael Stubblefield, president and CEO of Avantor, in a company press release. "The acquisition demonstrates our commitment to the growing biopharma market and to providing more comprehensive solutions to some of the world's most complex challenges in therapy and vaccine development."
Source: Avantor
